Biofrontera Drug Patent Portfolio
Biofrontera owns 1 orange book drug protected by 3 US patents Given below is the list of Biofrontera's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11235169 | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device | 15 Oct, 2040 | Active |
| US11540981 | Nanoemulsion formulation with improved stability and cell penetration | 07 Feb, 2028 | Active |
| US6559183 | Nano-emulsion of 5-aminolevulinic acid | 12 Nov, 2019 | Expired |
Latest Legal Activities on Biofrontera's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Biofrontera.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail O.P. Petition Decision | 21 Mar, 2024 | US11540981 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11540981 |
| Mail-Petition Decision - Denied | 19 Mar, 2024 | US11540981 |
| Petition Decision - Denied | 18 Mar, 2024 | US11540981 |
| O.P. Petition Decision | 18 Mar, 2024 | US11540981 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 06 Dec, 2023 | US11540981 |
| Petition Entered | 27 Apr, 2023 | US11540981 |
|
Recordation of Patent Grant Mailed
Critical
| 03 Jan, 2023 | US11540981 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 03 Jan, 2023 | US11540981 |
|
Email Notification
Critical
| 15 Dec, 2022 | US11540981 |
|
Issue Notification Mailed
Critical
| 14 Dec, 2022 | US11540981 |
|
Application Is Considered Ready for Issue
Critical
| 02 Dec, 2022 | US11540981 |
| Dispatch to FDC | 02 Dec, 2022 | US11540981 |
|
Issue Fee Payment Verified
Critical
| 30 Nov, 2022 | US11540981 |
|
Issue Fee Payment Received
Critical
| 30 Nov, 2022 | US11540981 |
Biofrontera's Family Patents
Biofrontera drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 5.3% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Biofrontera Drug List
Given below is the complete list of Biofrontera's drugs and the patents protecting them.
1. Ameluz
Ameluz is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11235169 | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
15 Oct, 2040
(16 years from now)
| Active |
| US11540981 | Nanoemulsion formulation with improved stability and cell penetration |
07 Feb, 2028
(3 years from now)
| Active |
| US6559183 | Nano-emulsion of 5-aminolevulinic acid |
12 Nov, 2019
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ameluz's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List